Global Valvular Heart Disease Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Valvular Heart Disease Treatment Market Analysis

The Valvular Heart Disease (VHD) Treatment Market is poised for significant growth driven by the increasing prevalence of valvular disorders globally. VHD occurs when one or more heart valves are damaged or diseased, affecting normal blood flow, often leading to serious health complications. Aging populations, particularly in developed nations, are contributing to the rise in VHD cases, further driving the demand for advanced treatments. Market growth is fueled by recent advancements in medical technology, including the development of minimally invasive procedures such as Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Repair (TMVR). These innovations offer lower risk, faster recovery times, and improved patient outcomes compared to traditional surgery. Moreover, bioprosthetic valves and innovative valve repair techniques have become key components in the treatment landscape, enhancing durability and reducing complications. Pharmaceutical treatments, including anticoagulants and diuretics, continue to play a vital role in managing symptoms and improving quality of life for patients. The market is also supported by increased healthcare investments and growing awareness, along with rising research in gene therapy and stem cell technologies, promising future breakthroughs.

Valvular Heart Disease Treatment Market Size

The global valvular heart disease treatment market size was valued at USD 6.28 billion in 2024 and is projected to reach USD 12.20 billion by 2032, with a CAGR of 8.39 % during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Valvular Heart Disease Treatment Market Trends

“Rising Preference for Bioprosthetic Valves and Transcatheter Therapies”

The Valvular Heart Disease Treatment Market is experiencing notable growth due to increasing advancements in minimally invasive surgeries, such as Transcatheter Aortic Valve Replacement (TAVR), which offer patients quicker recovery times and reduced complications compared to traditional open-heart surgeries. A key trend driving the market is the rising preference for bioprosthetic valves and transcatheter therapies, which are proving to be highly effective in treating aortic stenosis and mitral valve regurgitation. For instance, the approval and widespread adoption of TAVR procedures in countries such as the U.S. and those in Europe has significantly expanded treatment options for high-risk patients who are not suitable candidates for conventional surgery. In addition, the ongoing research into biocompatible materials and valve durability improvements, coupled with the increasing number of heart disease cases globally, is expected to drive further growth in the market. This trend reflects the shift toward patient-centered, less invasive treatment modalities and aligns with broader healthcare trends focused on improving patient outcomes and reducing hospital stays.

Report Scope and Valvular Heart Disease Treatment Market Segmentation         

Valvular Heart Disease Treatment Market Definition

Valvular Heart Disease Treatment refers to the medical and surgical interventions used to manage conditions where one or more of the heart's valves are damaged or diseased. These valves, which include the aortic, mitral, tricuspid, and pulmonary valves, control blood flow within the heart. When these valves do not function properly, it can lead to various complications such as heart failure, arrhythmias, or stroke.

Valvular Heart Disease Treatment Market Dynamics

Drivers

• Rising Prevalence of Cardiovascular Diseases

Rising prevalence of cardiovascular diseases, particularly heart valve disorders such as aortic stenosis and mitral regurgitation, is significantly driving the demand for advanced treatment options. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, claiming an estimated 17.9 million lives annually. Among these, valvular heart diseases account for a growing proportion, with studies indicating that over 5% of the elderly population worldwide suffers from aortic stenosis. In addition, a study published in The Lancet highlighted that mitral regurgitation affects approximately 2% of the global population, with prevalence increasing with age. As these conditions often require timely interventions to prevent complications, the demand for treatments such as surgical valve replacement, transcatheter aortic valve replacement (TAVR), and mitral valve repair continues to rise. This trend underscores the urgent need for innovative and effective solutions in the valvular heart disease treatment market, making it a critical growth driver.

•  Rising Aging Global Population

The aging global population is a major driver for the valvular heart disease treatment market, as older individuals are more susceptible to degenerative valve diseases such as aortic stenosis and mitral regurgitation. According to the United Nations, the global population aged 65 years or older is projected to reach 1.5 billion by 2050, nearly doubling from 727 million in 2020. Degenerative heart valve conditions are particularly common in this demographic, with studies indicating that approximately 13% of individuals aged 75 and older suffer from moderate to severe aortic stenosis. Moreover, the American College of Cardiology highlights that the prevalence of mitral regurgitation increases sharply with age, affecting up to 10% of individuals in their 80s. These statistics underscore the growing need for advanced valve repair and replacement therapies, including surgical and transcatheter interventions, to address this aging population's healthcare needs, driving significant growth in the valvular heart disease treatment market.

Opportunities

• Increasing Technological Advancements

Technological advancements in minimally invasive procedures, such as Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Repair (TMVR), are revolutionizing the valvular heart disease treatment landscape, presenting significant market opportunities. TAVR, for instance, allows patients with aortic stenosis, particularly those at high surgical risk, to undergo valve replacement without open-heart surgery. According to the American College of Cardiology, TAVR procedures surpassed surgical aortic valve replacements in the U.S. in 2021, demonstrating its growing acceptance. Similarly, TMVR technologies such as Abbott’s MitraClip have shown exceptional efficacy in treating mitral regurgitation, reducing symptoms and improving quality of life in patients who are not candidates for surgery. These innovations reduce hospital stays, minimize recovery times, and broaden treatment accessibility for elderly and high-risk patients. With continued advancements and regulatory approvals, the adoption of such technologies is expected to rise, creating robust growth opportunities in the valvular heart disease treatment market.

•  Increasing Government Initiatives and Funding

Government initiatives and funding are playing a pivotal role in driving the growth of the valvular heart disease treatment market by supporting cardiovascular research and subsidizing treatment programs. For instance, the U.S. National Institutes of Health (NIH) allocated over USD 2 billion in 2023 for cardiovascular research, enabling the development of innovative treatments and advanced technologies. Similarly, the European Union’s Horizon Europe program has prioritized cardiovascular health, providing grants for projects aimed at improving heart disease outcomes. In addition, government-funded healthcare programs, such as Medicare in the U.S., cover procedures such as Transcatheter Aortic Valve Replacement (TAVR) for eligible patients, making advanced treatments accessible to a broader population. These efforts encourage the adoption of cutting-edge therapies and enhance awareness and early diagnosis of heart valve disorders, fostering a positive impact on market growth. The continued focus on funding and policy support underscores the expanding opportunities in this sector.

Restraints/Challenges

• High Cost of Valvular Heart Disease Treatments

The high cost of valvular heart disease (VHD) treatments presents a significant challenge to patient access and market expansion, particularly for advanced procedures such as transcatheter aortic valve replacement (TAVR). In low- and middle-income countries, where healthcare budgets are constrained, these procedures are often out of reach for the majority of patients. For instance, in India, where healthcare expenditure per capita is low, access to such high-cost interventions is limited to a small subset of the population with private insurance or sufficient financial resources. This cost barrier restricts the adoption of advanced treatments and exacerbates healthcare inequities, as many patients in need of life-saving interventions are unable to afford them. From a market perspective, the prohibitive costs of VHD treatments create a significant hurdle for wider adoption and highlight the pressing need for cost-effective solutions that can improve accessibility without compromising quality or outcomes.

• Regulatory and Reimbursement Challenges

Regulatory and reimbursement challenges significantly impact the growth of the valvular heart disease (VHD) treatment market, particularly for advanced interventions such as transcatheter aortic valve replacement (TAVR). The regulatory approval process for such treatments requires extensive clinical trials to ensure safety and efficacy, which is both time-consuming and costly. For instance, in the European Union, gaining CE Mark approval for TAVR devices involves comprehensive evaluations, including post-market surveillance, adding to the time before products reach patients. Beyond regulatory hurdles, obtaining adequate reimbursement is equally challenging, especially in countries with limited healthcare budgets. For instance, in Brazil, where public healthcare systems face financial constraints, reimbursement for high-cost procedures such as TAVR is often delayed or insufficient, forcing patients to either pay out-of-pocket or forgo treatment altogether. These obstacles slow the introduction of innovative therapies into the market and limit their adoption, particularly in regions where financial and regulatory frameworks are less developed. Addressing these challenges is critical to expanding access to advanced VHD treatments and driving market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Valvular Heart Disease Treatment Market Scope

The market is segmented on the basis of product type, treatment type, age, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Patches
• Valves
• Grafts
• Medications
• Others

Treatment Type

• Medication
• Surgery
• Others

Age

• Children
• Adults

End User

• Hospitals
• Specialty Clinics
• Others

Valvular Heart Disease Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, treatment type, age, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

America and Europe are anticipated to witness significant growth due to a rise in research and development activities, a growing incidence of valvular heart diseases driven by poor lifestyle and dietary habits, technological advancements, and financial stability among a large portion of the population. In addition, strong support from both government and private sectors is contributing to a surge in healthcare expenditure, while increasing awareness about peritonitis treatment further boosts market demand. Furthermore, the enhancement of healthcare infrastructure in Europe plays a critical role in expanding the market within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Valvular Heart Disease Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Valvular Heart Disease Treatment Market Leaders Operating in the Market Are:

• LES LABORATOIRES SERVIER (France)
• Novosense (Sweden)
• Foldax (U.S.)
• LivaNova PLC (U.K.)
• Edwards Lifesciences Corporation (U.S.)
• Artivion, Inc (U.S.)
• NeoChord, Inc. (U.S.)
• CSL (Australia)
• Johnson & Johnson Services, Inc. (U.S.)
• Medtronic (Ireland)
• Boehringer Ingelheim International GmbH (Germany)
• Bayer AG (Germany)
• AstraZeneca (U.K.)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• LifeNet Health (U.S.)
• Abbott (U.S.)

Latest Developments in Valvular Heart Disease Treatment Market

• In June 2024, Medtronic plc, a global healthcare technology leader, announced the launch of its innovative Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to simplify the implant process and improve lifetime patient management, making it an ideal choice for cardiac surgeons and patients seeking a future-ready aortic valve solution
• In September 2024, Edwards Lifesciences launched the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with the Alterra adaptive prestent in Europe. This expansion of minimally invasive treatment options offers a broader range of patients with congenital heart conditions access to advanced care
• In May 2023, Edwards Lifesciences introduced the Sapien 3 Ultra Resilia valve in Europe. This transcatheter aortic valve replacement (TAVR) system is the first to incorporate the company's Resilia tissue technology, which is designed to improve valve durability
• In December 2022, Abbott announced the launch of its latest Navitor transcatheter aortic valve implantation (TAVI) system in India. This minimally invasive device is now available for patients with severe aortic stenosis who are at high or extreme surgical risk
• In September 2020, Boston Scientific Corporation initiated a controlled launch of the ACURATE neo2 Aortic Valve System in Europe. This advanced transcatheter aortic valve implantation (TAVI) system offers improved clinical performance over its predecessor and has expanded indications for patients with aortic stenosis, regardless of age or risk level, provided they are suitable candidates for therapy

SKU-59938